One of the open questions for both traditional and deep learning molecular generators is also how they should be benchmarked, compared and interpreted . Therefore, benchmarking studies of de novo drug design approaches are also the subject of ongoing research and much needed to ensure that these methods have conclusive real impact on new ligand discovery . However, the ultimate test of a de novo drug design method should always be prospective application in real projects with experimental validation of the generated molecules.